Stocks in play: Medicenna Therapeutics Corp.

Announced its financial results and operational highlights for the quarter ended June 30, 2022. Net loss for the quarter ended June 30 2022, was $4.2 million, or ($0.07) per share, compared to a net loss of $6.4 million, or ($0.12) per share, for the quarter ended June 30, 2021. The decrease in net loss for the quarter ended June 30, 2022, compared with the quarter ended June 30, 2021, was primarily a result of reduced research and development spending.. Medicenna Therapeutics Corp. shares T.MDNA are trading unchanged at $1.36.

Read:

• Mega Grocery Store Chains Listening to Customers’ Demands for Nutritious, Clean-Label Foods

• Innovative Food Stocks Responding to Conflict-, and Drought-Driven Food Supply Shocks

• Crypto Miners Finding Success While Shifting Towards Environmentally Sustainable Operations

• New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors

• As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges